Alan Russell
Vermogen: 799 344 $ op 31-05-2026
Vermogen: 799 344 $ op 31-05-2026
Alan Russell is the founder of Edgewise Therapeutics, Inc., founded in 2017, where the title held is Director & Chief Scientific Officer.
Former jobs include Associate Director-Muscle Biology & Therapeutics at Cytokinetics, Inc. from 2002 to 2010, and VP & Head-Muscle Metabolism Discovery Performance at GlaxoSmithKline LLC from 2014 to 2017.
Education includes undergraduate and doctorate degrees from the University of Bath.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 23.400 ( 0,02% ) | 799 344 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Oprichter | 01-01-2017 |
| Bedrijven | Functie | Einde |
|---|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Directeur/Bestuurslid | 01-09-2014 |
| CYTOKINETICS, INCORPORATED | Corporate Officer/Principal | 01-02-2010 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Cytokinetics, Inc.
Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
University of Bath
University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies for skeletal muscle diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau